{"id":58748,"date":"2024-02-28T05:26:30","date_gmt":"2024-02-28T05:26:30","guid":{"rendered":"https:\/\/medsname.com\/melorise\/"},"modified":"2026-05-01T10:49:14","modified_gmt":"2026-05-01T10:49:14","slug":"melorise","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/melorise\/","title":{"rendered":"Melorise"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Melorise?<\/h3>\n

Melorise<\/strong> \u03b5\u03af\u03bd\u03b1\u03b9 meloxicam tablet<\/strong> available in 7.5 mg and 15 mg<\/strong> strengths. Meloxicam is a preferential COX-2 NSAID<\/strong> with a long half-life (~20 hours) that permits \u03ba\u03b1\u03b8\u03b7\u03bc\u03b5\u03c1\u03b9\u03bd\u03ae \u03b4\u03cc\u03c3\u03b7<\/strong>. It is used for osteoarthritis (7.5 mg\/day), rheumatoid arthritis, and ankylosing spondylitis (15 mg\/day), and provides strong anti-inflammatory action with a modestly gentler GI profile than non-selective NSAIDs. Take with food.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n

Melorise<\/strong> \u03b5\u03af\u03bd\u03b1\u03b9 \u03ad\u03bd\u03b1 \u03b4\u03b9\u03c3\u03ba\u03af\u03bf \u03b3\u03b9\u03b1 \u03b1\u03c0\u03cc \u03c4\u03bf\u03c5 \u03c3\u03c4\u03cc\u03bc\u03b1\u03c4\u03bf\u03c2 \u03c7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7 \u03c4\u03b7\u03c2 meloxicam<\/strong>, an NSAID in the oxicam class with preferential activity against COX-2. At therapeutic doses (7.5–15 mg\/day), meloxicam inhibits COX-2 (the inflammation-driving isoform) substantially more than COX-1 (the stomach-protective isoform), giving a modest but real reduction in gastric-ulcer risk compared with classical non-selective NSAIDs like diclofenac, ibuprofen, and naproxen.<\/p>\n

Meloxicam has a long plasma half-life of approximately 20 hours, which allows simple \u03ba\u03b1\u03b8\u03b7\u03bc\u03b5\u03c1\u03b9\u03bd\u03ae \u03b4\u03cc\u03c3\u03b7<\/strong> and steady 24-hour anti-inflammatory cover — a practical advantage in chronic inflammatory arthritis where adherence matters.<\/p>\n

What Is Melorise Used For?<\/h2>\n
    \n
  • Osteoarthritis<\/strong> — 7.5 mg once daily (15 mg\/day if needed and tolerated)<\/li>\n
  • Rheumatoid arthritis<\/strong> — 15 mg once daily<\/li>\n
  • Ankylosing spondylitis<\/strong> — 15 mg once daily<\/li>\n
  • Acute musculoskeletal pain and injury<\/strong><\/li>\n
  • Juvenile idiopathic arthritis<\/strong> (specialist supervision, weight-based dosing)<\/li>\n
  • Primary dysmenorrhoea<\/strong> (off-label, short courses)<\/li>\n<\/ul>\n

    How Does Meloxicam Work?<\/h2>\n

    Meloxicam is a preferential COX-2 inhibitor. At therapeutic doses it shows roughly a 10-fold selectivity for COX-2 over COX-1, placing it between the non-selective NSAIDs (ibuprofen, diclofenac, naproxen) and the highly selective coxibs (celecoxib, etoricoxib). Clinical trials and meta-analyses confirm a modest but real reduction in GI ulcer and bleed rate compared with non-selective NSAIDs, while pain-relief efficacy is comparable.<\/p>\n

    Melorise Dosing<\/h2>\n
      \n
    • Osteoarthritis:<\/strong> 7.5 mg once daily with food (may increase to 15 mg\/day)<\/li>\n
    • Rheumatoid arthritis and ankylosing spondylitis:<\/strong> 15 mg once daily with food<\/li>\n
    • \u0397\u03bb\u03b9\u03ba\u03b9\u03c9\u03bc\u03ad\u03bd\u03bf\u03b9:<\/strong> start at 7.5 mg once daily<\/li>\n
    • \u039c\u03ad\u03b3\u03b9\u03c3\u03c4\u03bf:<\/strong> 15 mg\/day<\/li>\n
    • Renal impairment (mild-moderate):<\/strong> 7.5 mg\/day maximum; avoid if CrCl < 30 mL\/min<\/li>\n
    • \u0397\u03c0\u03b1\u03c4\u03b9\u03ba\u03ae \u03b4\u03c5\u03c3\u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1:<\/strong> 7.5 mg\/day; avoid in severe impairment<\/li>\n<\/ul>\n

      Swallow whole with water. Always take with food. If you miss a dose, take it as soon as you remember unless the next dose is due within 8 hours — then skip.<\/p>\n

      \n

      GI, cardiovascular, and renal safety.<\/strong> Meloxicam carries all the standard NSAID risks (GI ulcer, heart attack, stroke, acute kidney injury, raised blood pressure). Use at the lowest effective dose for the shortest clinically reasonable time. Consider adding a proton pump inhibitor for courses longer than 2–4 weeks. Patients with established cardiovascular disease should discuss with their doctor before starting.<\/p>\n<\/div>\n

      Who Should Not Take Melorise?<\/h2>\n